Last reviewed · How we verify

Ilaprazole + Amoxicillin

Il-Yang Pharm. Co., Ltd. · FDA-approved active Small molecule ✓ Verified May 2026

Ilaprazole + Amoxicillin is a Proton pump inhibitor + Beta-lactam antibiotic combination Small molecule drug developed by Il-Yang Pharm. Co., Ltd.. It is currently FDA-approved for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis. Also known as: Ilaprazole, Amoxicillin.

Ilaprazole inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection and healing peptic ulcers.

Ilaprazole is a small molecule used in combination with Amoxicillin, a sodium salt of the antibiotic amoxicillin, to treat conditions such as Helicobacter Pylori infection and peptic ulcer hemorrhage. This combination is also being studied for its potential to potentiate drug interactions and for its safety profile when used with other medications.

At a glance

Generic nameIlaprazole + Amoxicillin
Also known asIlaprazole, Amoxicillin
SponsorIl-Yang Pharm. Co., Ltd.
Drug classProton pump inhibitor + Beta-lactam antibiotic combination
TargetH+/K+-ATPase (ilaprazole); Bacterial cell wall peptidoglycan (amoxicillin)
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

Ilaprazole is a proton pump inhibitor that blocks the H+/K+-ATPase enzyme in gastric parietal cells, reducing stomach acid production and creating an environment where amoxicillin can effectively eliminate H. pylori. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis. This combination therapy addresses both the acid-related damage and the underlying bacterial infection responsible for most peptic ulcers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ilaprazole + Amoxicillin

What is Ilaprazole + Amoxicillin?

Ilaprazole + Amoxicillin is a Proton pump inhibitor + Beta-lactam antibiotic combination drug developed by Il-Yang Pharm. Co., Ltd., indicated for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis.

How does Ilaprazole + Amoxicillin work?

Ilaprazole inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection and healing peptic ulcers.

What is Ilaprazole + Amoxicillin used for?

Ilaprazole + Amoxicillin is indicated for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis.

Who makes Ilaprazole + Amoxicillin?

Ilaprazole + Amoxicillin is developed and marketed by Il-Yang Pharm. Co., Ltd. (see full Il-Yang Pharm. Co., Ltd. pipeline at /company/il-yang-pharm-co-ltd).

Is Ilaprazole + Amoxicillin also known as anything else?

Ilaprazole + Amoxicillin is also known as Ilaprazole, Amoxicillin.

What drug class is Ilaprazole + Amoxicillin in?

Ilaprazole + Amoxicillin belongs to the Proton pump inhibitor + Beta-lactam antibiotic combination class. See all Proton pump inhibitor + Beta-lactam antibiotic combination drugs at /class/proton-pump-inhibitor-beta-lactam-antibiotic-combination.

What development phase is Ilaprazole + Amoxicillin in?

Ilaprazole + Amoxicillin is FDA-approved (marketed).

What are the side effects of Ilaprazole + Amoxicillin?

Common side effects of Ilaprazole + Amoxicillin include Diarrhea, Nausea, Abdominal pain, Headache, Rash (amoxicillin-related).

What does Ilaprazole + Amoxicillin target?

Ilaprazole + Amoxicillin targets H+/K+-ATPase (ilaprazole); Bacterial cell wall peptidoglycan (amoxicillin) and is a Proton pump inhibitor + Beta-lactam antibiotic combination.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing